Subject: Fwd: FW: media update
From: nino mamaladze <[email-masked]>
To: [email-masked]
Date: Mon, 20 Apr 2015 15:54:06 +0000

-----Original Message-----
From: Davit Sergeenko <[email-masked]>
To: Nana Kavtaradze <[email-masked]>, tamar bodokia 
<[email-masked]>, nino mamaladze <[email-masked]>
Date: Mon, 20 Apr 2015 19:34:30 +0400
Subject: FW: media update

From:  Sonia Choi <[email-masked]>
Date:  Mon, 20 Apr 2015 16:17:15 +0100
To:  Davit Sergeenko <[email-masked]>, "Morgan, Juliette
(CDC/CGH/DGHP) ([email-masked])" <[email-masked]>, "Averhoff, Francisco
(CDC/OID/NCHHSTP) ([email-masked])" <[email-masked]>, Gregg Alton
<[email-masked]>, Graeme Robertson 
<[email-masked]>,
Enrico Magnanelli <[email-masked]>
Subject:  media update

Dear all 
 
We have been reaching out to media ahead of EASL and took the 
opportunity
to
mention to several reporters that there will be an announcement of an
important ³public health project² this week. We have not shared any
information about the project but have received initial interest from
Wall
Street Journal online, Reuters and Bloomberg.
 
Dear Minister  Would it be possible to receive a copy of your press
release
on official letterhead so we can share it with our media contacts at 
the
appropriate time? Could you also please advise if there is a set time
when
the release will be distributed tomorrow?
 
Many thanks,
Sonia
 
Sonia Choi
Senior Director, Public Affairs  EMEA
 
----------------------------------------------------------------------
---
---
------------------------------------------------------------
Gilead Sciences Europe Ltd€ Registered as a limited company in England
and
Wales € Registered number 05510315
Registered office: South Building € 2 Roundwood Avenue € Stockley
Park €
Uxbridge € UB11 1AF € England
Office: +44 (0)20 8587 2497    Mobile: +44 (0)7748 842890
----------------------------------------------------------------------
---
---
------------------------------------------------------------
 
DISCLAIMER If you have received this message in error, please contact 
the
sender immediately by return e-mail and notify the sender and then 
delete
this message (including any attachments) from your system. This
communication and any attachments contain information which is
confidential
and may also be legally privileged. It is for the exclusive use of the
intended recipient(s). If you are not the intended recipient(s) please
note
that any form of disclosure, distribution, copying or use of this
communication or the information in it or in any attachments is 
strictly
prohibited and may be unlawful. E-mail communications cannot be
guaranteed
to be secure or error free, as information could be intercepted,
corrupted,
amended, lost, destroyed, arrive late or incomplete, or contain 
viruses.
Gilead does not accept liability for any such matters or their
consequences.
Anyone who communicates with Gilead by e-mail is taken to accept the
risks
in doing so. Gilead has taken every reasonable precaution to ensure 
that
any
attachment to this e-mail has been swept for viruses. However, Gilead
cannot
accept liability for any damage sustained as a result of viruses and
would
advise that you carry out your own virus checks before opening any
attachment. Gilead Sciences Europe Ltd ; Registered as a limited 
company
in
England and Wales ; Registered number 5510315 Registered office: South
Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ;
England